新辅助mFOLFIRINOX方案与mFOLFIRINOX方案联合放疗用于可切除边缘性胰腺癌患者——A021501试验 - Suppr | 超能文献

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.

作者信息

Hintz Brace, Lee Vincent J

机构信息

Department of Radiation Oncology, The Permanente Medical Group, South Sacramento, California.

出版信息

JAMA Oncol. 2023 Feb 1;9(2):277. doi: 10.1001/jamaoncol.2022.6144.

DOI:10.1001/jamaoncol.2022.6144

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.新辅助mFOLFIRINOX方案与mFOLFIRINOX方案联合放疗用于可切除边缘性胰腺癌患者——A021501试验

JAMA Oncol. 2023 Feb 1;9(2):277. doi: 10.1001/jamaoncol.2022.6144.

2

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.新辅助mFOLFIRINOX方案与mFOLFIRINOX方案联合放疗治疗可切除边缘胰腺癌患者——A021501试验

JAMA Oncol. 2023 Feb 1;9(2):275. doi: 10.1001/jamaoncol.2022.6135.

3

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.新辅助mFOLFIRINOX方案与mFOLFIRINOX方案联合放疗用于可切除边缘胰腺癌患者的疗效比较——A021501试验

JAMA Oncol. 2023 Feb 1;9(2):276-277. doi: 10.1001/jamaoncol.2022.6141.

4

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial.新辅助mFOLFIRINOX方案与mFOLFIRINOX方案联合放疗用于可切除边缘胰腺癌患者的疗效比较——A021501试验

JAMA Oncol. 2023 Feb 1;9(2):275-276. doi: 10.1001/jamaoncol.2022.6138.

5

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer-The A021501 Trial-Reply.新辅助mFOLFIRINOX方案与mFOLFIRINOX方案联合放疗用于可切除边缘的胰腺癌患者——A021501试验——回复

JAMA Oncol. 2023 Feb 1;9(2):277-278. doi: 10.1001/jamaoncol.2022.6147.

6

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.术前 mFOLFIRINOX 对比 mFOLFIRINOX 联合短程放疗治疗边界可切除胰腺腺癌的疗效：A021501 期随机临床试验。

JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.

7

Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas.联盟 A021501 的放射治疗质量保证分析：术前 mFOLFIRINOX 或 mFOLFIRINOX 联合低分割放射治疗局部可切除胰腺腺癌。

Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):111-119. doi: 10.1016/j.ijrobp.2024.03.013. Epub 2024 Mar 15.

8

[Neoadjuvant and adjuvant treatment of pancreatic cancer].[胰腺癌的新辅助治疗和辅助治疗]

Chirurg. 2020 Aug;91(8):636-641. doi: 10.1007/s00104-020-01169-9.

9

Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population.改良 FOLFIRINOX 方案新辅助治疗与中国局部晚期胰腺癌患者结局的相关性。

Oncologist. 2019 Mar;24(3):301-e93. doi: 10.1634/theoncologist.2018-0696. Epub 2018 Nov 20.

10

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.AGITG 主计划：一项改良 FOLFIRINOX 单独或联合立体定向体部放疗治疗高危和局部进展期胰腺癌患者的随机 II 期研究。

BMC Cancer. 2021 Aug 19;21(1):936. doi: 10.1186/s12885-021-08666-y.

引用本文的文献

1

Updates in Immunotherapy for Pancreatic Cancer.胰腺癌免疫治疗的进展

J Clin Med. 2024 Oct 26;13(21):6419. doi: 10.3390/jcm13216419.